BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 29634721)

  • 1. Twelve-month clinical outcomes of 206 patients with chronic pulmonary aspergillosis.
    Bongomin F; Harris C; Hayes G; Kosmidis C; Denning DW
    PLoS One; 2018; 13(4):e0193732. PubMed ID: 29634721
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of high baseline Aspergillus-specific IgG levels on weight and quality-of-life outcomes of patients with chronic pulmonary aspergillosis.
    Bongomin F; Garcez T; Denning DW
    Med Mycol; 2020 Oct; 58(7):1000-1004. PubMed ID: 32343313
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High detection rate of azole-resistant Aspergillus fumigatus after treatment with azole antifungal drugs among patients with chronic pulmonary aspergillosis in a single hospital setting with low azole resistance.
    Takeda K; Suzuki J; Watanabe A; Arai T; Koiwa T; Shinfuku K; Narumoto O; Kawashima M; Fukami T; Tamura A; Nagai H; Matsui H; Kamei K
    Med Mycol; 2021 Apr; 59(4):327-334. PubMed ID: 32642756
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Positive Aspergillus PCR as a marker of azole resistance or sub-therapeutic antifungal therapy in patients with chronic pulmonary aspergillosis.
    Moazam S; Eades CP; Muldoon EG; Moore CB; Richardson MD; Rautemaa-Richardson R
    Mycoses; 2020 Apr; 63(4):376-381. PubMed ID: 31981256
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pulsed echinocandin therapy in azole intolerant or multiresistant chronic pulmonary aspergillosis: A retrospective review at a UK tertiary centre.
    Osborne W; Fernandes M; Brooks S; Grist E; Sayer C; Hansell DM; Wilson R; Shah A; Loebinger MR
    Clin Respir J; 2020 Jun; 14(6):571-577. PubMed ID: 32077238
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Isavuconazole and voriconazole for the treatment of chronic pulmonary aspergillosis: A retrospective comparison of rates of adverse events.
    Bongomin F; Maguire N; Moore CB; Felton T; Rautemaa-Richardson R
    Mycoses; 2019 Mar; 62(3):217-222. PubMed ID: 30570179
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of posaconazole salvage therapy in chronic pulmonary aspergillosis using predefined response criteria.
    Rodriguez-Goncer I; Harris C; Kosmidis C; Muldoon EG; Newton PJ; Denning DW
    Int J Antimicrob Agents; 2018 Aug; 52(2):258-264. PubMed ID: 29906567
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Voriconazole for chronic pulmonary aspergillosis: a prospective multicenter trial.
    Cadranel J; Philippe B; Hennequin C; Bergeron A; Bergot E; Bourdin A; Cottin V; Jeanfaivre T; Godet C; Pineau M; Germaud P
    Eur J Clin Microbiol Infect Dis; 2012 Nov; 31(11):3231-9. PubMed ID: 22782438
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of chronic pulmonary aspergillosis with voriconazole: review of a case series.
    Cucchetto G; Cazzadori A; Conti M; Cascio GL; Braggio P; Concia E
    Infection; 2015 Jun; 43(3):277-86. PubMed ID: 25432571
    [TBL] [Abstract][Full Text] [Related]  

  • 10. COVID-19-associated pulmonary aspergillosis (CAPA) in Iranian patients admitted with severe COVID-19 pneumonia.
    Erami M; Hashemi SJ; Raiesi O; Fattahi M; Getso MI; Momen-Heravi M; Daie Ghazvini R; Khodavaisy S; Parviz S; Mehri N; Babaei M
    Infection; 2023 Feb; 51(1):223-230. PubMed ID: 36107379
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chronic Pulmonary Aspergillosis: Clinical Presentation and Management.
    Evans TJ; Lawal A; Kosmidis C; Denning DW
    Semin Respir Crit Care Med; 2024 Feb; 45(1):88-101. PubMed ID: 38154471
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical efficacy of sequential therapy with voriconazole on COPD patients in acute phase with pulmonary aspergillosis and effects on cytokines and pulmonary functions.
    Du JF; Chi YM; Song Z; Di QG; Shi J; Lv J; Mai ZT; Li M; Sun BH; Jiang MM
    Eur Rev Med Pharmacol Sci; 2018 Mar; 22(6):1837-1842. PubMed ID: 29630134
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of voriconazole in the treatment of chronic pulmonary aspergillosis: experience in Japan.
    Saito T; Fujiuchi S; Tao Y; Sasaki Y; Ogawa K; Suzuki K; Tada A; Kuba M; Kato T; Kawabata M; Kurashima A; Sakatani M;
    Infection; 2012 Dec; 40(6):661-7. PubMed ID: 22956473
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tolerability of oral itraconazole and voriconazole for the treatment of chronic pulmonary aspergillosis: A systematic review and meta-analysis.
    Olum R; Baluku JB; Kazibwe A; Russell L; Bongomin F
    PLoS One; 2020; 15(10):e0240374. PubMed ID: 33052954
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An overview of the available treatments for chronic cavitary pulmonary aspergillosis.
    Sehgal IS; Dhooria S; Muthu V; Prasad KT; Agarwal R
    Expert Rev Respir Med; 2020 Jul; 14(7):715-727. PubMed ID: 32249630
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An evaluation of nebulised amphotericin B deoxycholate (Fungizone
    Otu AA; Langridge P; Denning DW
    Mycoses; 2019 Nov; 62(11):1049-1055. PubMed ID: 31479538
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Voriconazole treatment for subacute invasive and chronic pulmonary aspergillosis.
    Sambatakou H; Dupont B; Lode H; Denning DW
    Am J Med; 2006 Jun; 119(6):527.e17-24. PubMed ID: 16750972
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A prospective survey of Aspergillus spp. in respiratory tract samples: prevalence, clinical impact and antifungal susceptibility.
    Mortensen KL; Johansen HK; Fuursted K; Knudsen JD; Gahrn-Hansen B; Jensen RH; Howard SJ; Arendrup MC
    Eur J Clin Microbiol Infect Dis; 2011 Nov; 30(11):1355-63. PubMed ID: 21541671
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term antifungal treatment improves health status in patients with chronic pulmonary aspergillosis: a longitudinal analysis.
    Al-Shair K; Atherton GT; Harris C; Ratcliffe L; Newton PJ; Denning DW
    Clin Infect Dis; 2013 Sep; 57(6):828-35. PubMed ID: 23788240
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correlation between triazole treatment history and susceptibility in clinically isolated Aspergillus fumigatus.
    Tashiro M; Izumikawa K; Hirano K; Ide S; Mihara T; Hosogaya N; Takazono T; Morinaga Y; Nakamura S; Kurihara S; Imamura Y; Miyazaki T; Nishino T; Tsukamoto M; Kakeya H; Yamamoto Y; Yanagihara K; Yasuoka A; Tashiro T; Kohno S
    Antimicrob Agents Chemother; 2012 Sep; 56(9):4870-5. PubMed ID: 22751542
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.